Pharma wins reduction in data requirements for EU EVMPD product database
This article was originally published in SRA
Following strong lobbying by the pharmaceutical industry, the European Medicines Agency has substantially reduced the amount of information that companies must provide by 2 July on all the products they market in the EU1,2. Industry will be relieved at the move, having pushed hard for a delay to the deadline or at least a reduction in the scope of the requirement.
You may also be interested in...
EU and US regulators have opposing views when it comes to Merck's applications for a new indication and new dosing schedule for the company's successful PD-1 inhibitor Keytruda.
Regulators have pulled out all the stops in their efforts to get the Ebola vaccine to the marketing authorization stage in Africa.
At the end of the Brexit transition period, the UK will be charting its own course through the often choppy seas of medicines regulation. While it plans to retain the existing EU rules that have been transposed into domestic legislation, it also wants the freedom to tailor its regulations in areas like clinical trials, advanced therapies and product labeling.